hVIVO (LON:HVO) Trading Down 48.6% - Here's Why

hVIVO plc (LON:HVO - Get Free Report) shares were down 48.6% during mid-day trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.32 ($0.11). Approximately 74,283,875 shares were traded during mid-day trading, an increase of 2,124% from the average daily volume of 3,339,384 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analysts Set New Price Targets

Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a research report on Friday.

hVIVO Price Performance

The stock has a fifty day moving average of GBX 16.16 and a 200-day moving average of GBX 18.13. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The firm has a market capitalization of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities analysts predict that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

Insider Buying and Selling

In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,459.93). 14.03% of the stock is currently owned by corporate insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.